XML 107 R96.htm IDEA: XBRL DOCUMENT v3.25.1
Liability Related to the Sale of Future Royalties and Milestones (Narrative) (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 20, 2018
Jan. 19, 2018
Jan. 06, 2018
May 31, 2024
Sep. 30, 2018
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2020
May 06, 2024
Nov. 30, 2022
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Non-cash interest expense           $ 117,342,000            
Royalties received, recognised revenue           103,463,000 $ 156,314,000 $ 98,024,000        
Royalty or milestone revenue recognized           14,000            
Warrants, exercise price                       $ 56.8
Proceeds from liability related to sale of future royalties and milestones           63,879,000            
Fair value of the Purchaser Upsize Option           69,000            
Royalty Sales Milestone [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Royalties received, recognised revenue               25,250,000        
Incyte Corporation and Merck Sharpe & Dohme [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Percentage of future milestones retained 90.00%                      
Percentage of future royalties retained 67.00%                      
Incyte Corporation [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Royalties received, recognised revenue           0            
GSK Agreements [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Non-cash royalty revenue recognized           101,000,000 114,600,000 45,300,000        
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Percentage of purchase of worldwide rights to receive royalties   100.00%                    
Gross proceeds received for royalty rights   $ 190,000,000                    
Reimbursed HCR for transaction costs   100,000                    
Transaction costs incurred   500,000                    
Non-cash royalty revenue recognized           101,000,000 114,600,000 45,300,000        
Non-cash interest expense           $ 106,700,000 100,300,000 62,700,000        
Effective annual interest rate           23.80%            
Prospective effective annual interest rate           24.60%            
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Royalty Sales Milestone [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Royalties received, recognised revenue               25,300,000        
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Minimum [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Sales milestones target                 $ 2,750,000,000      
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Maximum [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Potential milestone payments receivable   40,400,000                    
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Prior to 2024 [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Potential milestone payments receivable   15,100,000               $ 15,100,000    
Sales milestones target     $ 2,000,000,000             $ 2,000,000,000    
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Prior to 2026 [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Potential milestone payments receivable   $ 25,300,000                    
Sales milestones target     $ 2,750,000,000                  
XOMA US [Member] | Royalty Purchase Agreement [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Proceeds from royalties and milestones payment $ 15,000,000                      
Liability related to sale of future royalties and milestones $ 15,000,000                      
Royalty or milestone revenue recognized           $ 0 $ 0 $ 0        
XOMA US [Member] | Royalty Purchase Agreement [Member] | Incyte Corporation and Merck Sharpe & Dohme [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Percentage of sold future royalties right to receive 33.00%                      
Percentage of sold future milestones right to receive 10.00%                      
XOMA US [Member] | Royalty Purchase Agreement [Member] | Incyte Corporation [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Proceeds from milestones recognized         $ 5,000,000              
Ligand Pharmaceuticals Incorporated [Member] | Common Stock [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Warrants issued to purchase shars of common stock       867,052             867,052  
Warrants, exercise price       $ 17.3             $ 17.3  
Ligand Pharmaceuticals Incorporated [Member] | Purchase Agreement [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Non-cash interest expense           $ 10,600,000            
Effective annual interest rate           24.30%            
Liability related to sale of future royalties and milestones           $ 63,879,000            
Percentage of synthetic royalty on worldwide net sales of purchased assets       2.625%                
Percentage reduction in amounts payable upon overall payments due exceeding specified return hurdle       50.00%                
Percentage increase in synthetic royalty based on certain future events       1.00%                
Consideration on sale of purchased assets gross       $ 75,000,000                
Reimbursable expenses       900,000                
Time-based option to invest, additional amount       $ 25,000,000                
Gross proceeds from purchase agreement           75,000,000            
Fair value of the Purchaser Upsize Option           $ 69,200            
Ligand Pharmaceuticals Incorporated [Member] | Covered License Agreements [Member] | Purchase Agreement [Member]                        
Liability Related To Sale Of Future Royalties And Milestones [Line Items]                        
Percentage of sale of development, regulatory and commercial milestone payments eligible to receive       31.875%                
Percentage of royalties receipts       18.75%